Réf. :HematoStat.net ; 2 (12) : R63 Brink M, Meeuwes FO, van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, et al. Impact of etoposide and ASCT on survival among […]

Réf. :HematoStat.net ; 2 (12) : R62 Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult […]

Réf. :HematoStat.net ; 2 (12) : R61 Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Bhat SA, Gambril J, Azali L, Chen ST, Rosen L, Palettas M, et al. […]

Réf. :HematoStat.net ; 2 (12) : R60 Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol […]

Réf. :HematoStat.net ; 2 (12) : R59 Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Döhner H, Wei AH, Roboz […]

Association azacitidine et ivosidenib : un nouveau standard de traitement ? Réf. HematoStat.net ; 2(7) : U14 - Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid ...

Réf. :HematoStat.net ; 2 (6) : R51 Lagerlöf I, Fohlin H, Enblad G, Glimelius B, Goldkuhl C, Palma M, et al. Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage […]

Réf. :HematoStat.net ; 2 (6) : R50 Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea […]

Réf. :HematoStat.net ; 2 (6) : R49 Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, et al. Dose-adjusted EPOCH and rituximab for the treatment of double […]

Réf. :HematoStat.net ; 2 (6) : R48 Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy […]